26.04.2026, 1105 Zeichen

Marinomed: Marinomed Biotech AG, a healthcare-focused innovator committed to improving patient outcomes, announced its strategic entry into the compounding business. The company anticipates that several customers will commission services based on the Marinosolv technology in the short to medium term. First revenues are expected in Q4 2026 or beginning of 2027. The company plans to cover its operating costs from its service business. This expansion of its capabilities to deliver customized solutions based on its Marinosolv technology tailored to the evolving needs of customers and partners positions the company to meet growing global demand for customized medicines tailored to individual patient needs, physician preferences, and unmet therapeutic requirements. By using Marinosolv technology, Marinomed will leverage advanced solubilization capabilities that allow pharmacies a reproducible and standardized process for producing compounded products effectively.
Marinomed Biotech: weekly performance: -0.72%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (22/04/2026)

Christian Drastil: Wiener Börse Plausch

Wiener Börse Party #1199: ATX schwächer, Sommerloch als Beleidigung, oekostrom-Season startet, Bawag-Serie und am Ende Only You

Bildnachweis

Aktien auf dem Radar:Porr, Kapsch TrafficCom, Flughafen Wien, EuroTeleSites AG, RHI Magnesita, Austriacard Holdings AG, OMV, Telekom Austria, voestalpine, Verbund, SBO, Lenzing, Strabag, FACC, Bawag, Andritz, Addiko Bank, Frequentis, RBI, Semperit, BKS Bank Stamm, Marinomed Biotech, Amag, CPI Europe AG, Österreichische Post, UBM, IBM, Goldman Sachs, Commerzbank, Fresenius Medical Care, Mercedes-Benz Group.

---